Pancreatic Cancer Research

ResearcherChangzhou No.2 People's HospitalActive in the last 2 years

Feifei Wei

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6048-8894; OpenAlex author ID A5088923961. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers

Papers 4

  1. LncRNA-NEAT1 inhibits the occurrence and development of pancreatic cancer through spongy miR-146b-5p/traf6. Co-author DOI 10.1080/02648725.2023.2192059↗
  2. The value of a metabolic and immune-related gene signature and adjuvant therapeutic response in pancreatic cancer. Last author DOI 10.3389/fgene.2024.1475378↗
  3. Aspirin Regulates Gemcitabine Resistance in Pancreatic Cancer via Inhibiting the PI3K/Akt/mTOR Signaling Pathway and Reversing Epithelial-mesenchymal Transition Co-author DOI 10.21203/rs.3.rs-818856/v1↗
  4. Significance of MUC2 gene methylation detection in pancreatic cancer diagnosis. Co-author DOI 10.1016/j.pan.2019.09.012↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kequn Xu · 4 shared papers, 2019–2024 · strength 0.70
  2. Hanyu Zhou · 2 shared papers, 2019–2021 · strength 0.23
  3. Danlei Ni · 1 shared paper, 2024 · strength 0.23
  4. Yun Xiao · 1 shared paper, 2021 · strength 0.13
  5. Yuqing Cheng · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.